Skip to main content
Premium Trial:

Request an Annual Quote

Activiomics Lands $806K Investment

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – UK phosphoproteomics firm Activiomics today announced it has received a £500,000 ($806,715) investment, which it will use to further build partnerships with pharmaceutical and biotech firms and to identify novel biomarkers.

Leading the round was IP Group. Additional investors included IP Venture Fund and members of Activiomics' management.

The company, based in London, is a spinout of the Institute of Cancer, Barts and the London School of Medicine and Dentistry at Queen Mary, University of London. Its flagship technology called Targeted In-Depth Quantification of Cell Signaling, or TIQUAS, combines phosphoproteomics, mass spectrometry, and a proprietary database and software to investigate cell signaling pathways.

According to the firm, its technology has applications in biomarker and drug discovery in disease areas including oncology and inflammation. In December, Activiomics inked an agreement with biopharma firm UCB for the use of TIQUAS for the analysis and interpretation of cell-signaling pathway activity.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.